Cargando…
Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea
BACKGROUND: We investigated the long-term effect of AST-120, which has been proposed as a therapeutic option against renal disease progression, in patients with advanced chronic kidney disease (CKD). METHODS: We performed post-hoc analysis with a per-protocol group of the K-STAR study (Kremezin stud...
Autores principales: | Cha, Ran-hui, Kang, Shin Wook, Park, Cheol Whee, Cha, Dae Ryong, Na, Ki Young, Kim, Sung Gyun, Yoon, Sun Ae, Kim, Sejoong, Han, Sang Youb, Park, Jung Hwan, Chang, Jae Hyun, Lim, Chun Soo, Kim, Yon Su |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Nephrology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331977/ https://www.ncbi.nlm.nih.gov/pubmed/28392999 http://dx.doi.org/10.23876/j.krcp.2017.36.1.68 |
Ejemplares similares
-
Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea [Volume 36, Issue 1, March 2017, Pages 68–78]
por: Cha, Ran-hui, et al.
Publicado: (2018) -
Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease
por: Baek, Seon Ha, et al.
Publicado: (2019) -
Serum Anion Gap Predicts All-Cause Mortality in Patients with Advanced Chronic Kidney Disease: A Retrospective Analysis of a Randomized Controlled Study
por: Lee, Sung Woo, et al.
Publicado: (2016) -
Review of the efficacy of AST-120 (KREMEZIN(®)) on renal function in chronic kidney disease patients
por: Asai, Mayumi, et al.
Publicado: (2019) -
Inhibition of Renal Stellate Cell Activation Reduces Renal Fibrosis
por: Cha, Jin Joo, et al.
Publicado: (2020)